Department of Laboratory Diagnostics,University Hospital Center Zagreb, Zagreb, Croatia.
Referral Center for Pediatrics Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Zagreb, Croatia.
Biochem Med (Zagreb). 2022 Feb 15;32(1):010707. doi: 10.11613/BM.2022.010707.
This study reevaluated von Willebrand disease (vWD) diagnosis in a Croatian paediatric cohort by combining bleeding scores (BS), phenotypic laboratory testing, and next-generation sequencing (NGS).
A total of 25 children (11 males and 14 females, median age 10 years, from 2 to 17) previously diagnosed with vWD were included. BS were calculated using an online bleeding assessment tool. Phenotypic laboratory analyses included platelet count, platelet function analyser closure times, prothrombin time, activated partial thromboplastin time, von Willebrand factor antigen (vWF:Ag), vWF gain-of-function mutant glycoprotein Ib binding activity (vWF:GPIbM), vWF collagen binding activity (vWF:CBA), factor VIII activity (FVIII:C) and multimeric analysis. Next-generation sequencing covered regions of both vWF and FVIII genes and was performed on MiSeq (Illumina, San Diego, USA).
Disease-associated variants identified in 15 patients comprised 11 distinct heterozygous vWF gene variants in 13 patients and one novel FVIII gene variant (p.Glu2085Lys) in two male siblings. Four vWF variants were novel (p.Gln499Pro, p.Asp1277Tyr, p.Asp1277His, p.Lys1491Glu). Three patients without distinctive variants had vWF:GPIbM between 30 and 50%. Patients with identified vWF gene variants had statistically significant lower values of vWF:GPIbM (P = 0.002), vWF:Ag (P = 0.007), vWF:CBA (P < 0.001) and FVIII:C (P = 0.002), compared to those without. Correlations between BS and phenotypic laboratory test results were not statistically significant for either of the tests.
The applied diagnostic approach confirmed the diagnosis of vWD in 13 patients and mild haemophilia A in two. Limited utility of BS in the paediatric population was evidenced.
本研究通过结合出血评分(BS)、表型实验室检测和下一代测序(NGS),重新评估了克罗地亚儿科队列中的血管性血友病(vWD)诊断。
共纳入 25 名患儿(男 11 名,女 14 名,中位年龄 10 岁,年龄 2 至 17 岁),均为先前诊断为 vWD 的患儿。采用在线出血评估工具计算 BS。表型实验室分析包括血小板计数、血小板功能分析仪封闭时间、凝血酶原时间、活化部分凝血活酶时间、血管性血友病因子抗原(vWF:Ag)、血管性血友病因子 gain-of-function 突变糖蛋白 Ib 结合活性(vWF:GPIbM)、血管性血友病因子胶原结合活性(vWF:CBA)、VIII 因子活性(FVIII:C)和多聚体分析。NGS 覆盖 vWF 和 FVIII 基因的区域,并在 MiSeq(Illumina,圣地亚哥,美国)上进行。
在 15 名患者中发现了与疾病相关的变异,其中 13 名患者存在 11 种不同的杂合 vWF 基因突变,两名男性同胞存在一种新的 FVIII 基因突变(p.Glu2085Lys)。4 种 vWF 变异为新发现的(p.Gln499Pro、p.Asp1277Tyr、p.Asp1277His、p.Lys1491Glu)。3 名无明显变异的患者 vWF:GPIbM 在 30%至 50%之间。与无 vWF 基因突变的患者相比,携带 vWF 基因突变的患者 vWF:GPIbM(P = 0.002)、vWF:Ag(P = 0.007)、vWF:CBA(P < 0.001)和 FVIII:C(P = 0.002)显著降低。BS 和表型实验室检测结果之间的相关性在任何一种检测中均无统计学意义。
应用的诊断方法在 13 名患者中确认了 vWD 的诊断,在 2 名患者中确认了轻度血友病 A。在儿科人群中,BS 的应用有限。